Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID
NCT00100828
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well irinotecan works in treating patients with metastatic or inoperable thyroid cancer.

Key Dates

Start date
Nov 30, 2004
Status verified
Nov 2018
Primary completion
Nov 30, 2008
Completion
Nov 30, 2008

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Irinotecan

Primary Outcome Measure

Response Rate [ Time Frame: Every 2 cycles ]

Locations (2)

FacilityCityStateZIPSite coordinators
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreMaryland21231-2410-
University of Michigan Comprehensive Cancer CenterAnn ArborMichigan48109-0942-

Find similar trials in Baltimore, MD

By condition
Head and neck cancer
By specialty
OncologyENT
By research site
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Baltimore, MDUniversity of Michigan Comprehensive Cancer Center· Ann Arbor, MI

Related Studies